Other equities research analysts have also recently issued research reports about the stock. Liberum Capital reissued a buy rating and set a GBX 248 ($3.27) target price on shares of Puretech Health PLC in a research report on Wednesday, July 12th. N+1 Singer reissued a buy rating on shares of Puretech Health PLC in a research report on Wednesday, August 30th. Numis Securities Ltd reissued a buy rating and set a GBX 246 ($3.25) target price on shares of Puretech Health PLC in a research report on Wednesday, August 30th. Finally, Jefferies Group LLC reissued a buy rating and set a GBX 225 ($2.97) target price on shares of Puretech Health PLC in a research report on Wednesday, August 30th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and a consensus price target of GBX 242.80 ($3.20).
Puretech Health PLC (PRTC) opened at GBX 130 ($1.72) on Tuesday.
ILLEGAL ACTIVITY NOTICE: This piece was published by BBNS and is owned by of BBNS. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://baseballnewssource.com/markets/puretech-health-plcs-prtc-buy-rating-reaffirmed-at-peel-hunt/1746197.html.
About Puretech Health PLC
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with our FREE daily email newsletter.